Olgu Sunumu
Yıl 2018,
Cilt: 10 Sayı: 6, 34 - 36, 28.11.2018
Öz
Abstract
Metabolic syndrome (MetS) is a condition where multiple risk factors coexist, increase the risk of developing diabetes and cardiovascular disease. Almost one in four adultshave MetS worldwide. Although MetS is commonly seen, it is overlooked in the diagnosis. Therefore, patients carrying any of the MetS criteria should be evaluated in termsof metabolic syndrome. The aim of this study was to discuss the management of metabolic syndrome in a primary care setting via a patient admitted to the family medicineoutpatient clinic.
Anahtar Kelimeler
Kaynakça
- Kaynaklar 1.TEMD Obezite LM, Hipertansiyon Çalışma Grubu TÜRKİ-YE ENDOKRİNOLOJİ ve METABOLİZMA DERNEĞİ 2018. 2.Samson SL, Garber AJ. Metabolic syndrome. Endocrinologyand Metabolism Clinics. 2014;43(1):1-23. 3.Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH,Franklin BA, et al. Diagnosis and management of the meta-bolic syndrome: an American Heart Association/National He-art, Lung, and Blood Institute scientific statement. Circulati-on. 2005;112(17):2735-52. 4.Onat AT. Tıp Dünyasının Kronik Hastalıklara Yaklaşımına Ön-cülük [electronic resource]. Edited by Altan ONAT İstanbul:Logos Yayıncılık. 2017;2017:180. 5.Ford ES, Giles WH, Dietz WH. Prevalence of the metabolicsyndrome among US adults: findings from the third NationalHealth and Nutrition Examination Survey. Jama.2002;287(3):356-9. 6.Nelson MR. Managing'metabolic syndrome'and multiple riskfactors. Australian family physician. 2004;33(4):201. 7.Grundy SM. Metabolic syndrome pandemic. Arteriosclerosis,thrombosis, and vascular biology. 2008;28(4):629-36. 8.Arslan M, Atmaca A, Ayvaz G, Başkal N, Beyhan Z, Bolu E,et al. METABOLİK SENDROM KILAVUZU. 2009. 9.Reaven GM. Banting lecture 1988: role of insulin resistancein human disease. Nutrition. 1997;13(1):64. 10.Alberti KGMM, Zimmet Pf. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diag-nosis and classification of diabetes mellitus. Provisional reportof a WHO consultation. Diabetic medicine. 1998;15(7):539-53. 11.Syndrome M. Time for Action. DARWIN DEEN, MD, MS, Al-bert Einstein College of Medicine of Yeshiva University, Bronx,New York-DARWIN DEEN, MD, MS, Albert Einstein Colle-ge of Medicine of Yeshiva University, Bronx, New York. 2004. 12.Magkos F, Yannakoulia M, Chan JL, Mantzoros CS. Mana-gement of the metabolic syndrome and type 2 diabetes thro-ugh lifestyle modification. Annual review of nutrition.2009;29:223-56. 13.Bozkurt B, Aguilar D, Deswal A, Dunbar SB, Francis GS, Hor-wich T, et al. Contributory risk and management of comorbi-dities of hypertension, obesity, diabetes mellitus, hyperlipide-mia, and metabolic syndrome in chronic heart failure: a sci-entific statement from the American Heart Association. Cir-culation. 2016;134(23):e535-e78. 14.Gregg EW, Cauley JA, Stone K, Thompson TJ, Bauer DC, Cum-mings SR, et al. Relationship of changes in physical activityand mortality among older women. Jama. 2003;289(18):2379-86. 15.Willett WC, Sacks F, Trichopoulou A, Drescher G, Ferro-Luz-zi A, Helsing E, et al. Mediterranean diet pyramid: a cultu-ral model for healthy eating. The American journal of clini-cal nutrition. 1995;61(6):1402S-6S. 16.Carapetis M, Phillips P. Eat less, walk more. Enjoyable ea-ting for type 2 diabetes. Australian family physician.2002;31(12):1065. 17.Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lac-hin JM, Walker EA, et al. Reduction in the incidence of type2 diabetes with lifestyle intervention or metformin. The NewEngland journal of medicine. 2002;346(6):393-403. 18.Pearson TA, Blair SN, Daniels SR, Eckel RH, Fair JM, Fort-mann SP, et al. AHA guidelines for primary prevention of cardiovascular disease and stroke: 2002 update: consensus pa-nel guide to comprehensive risk reduction for adult patientswithout coronary or other atherosclerotic vascular diseases.Circulation. 2002;106(3):388-91. 19.Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Bee-re PA, et al. Primary prevention of acute coronary events withlovastatin in men and women with average cholesterol levels:results of AFCAPS/TexCAPS. Jama. 1998;279(20):1615-22. 20.Beckman TJ. Regular screening in type 2 diabetes: A mnemo-nic approach for improving compliance, detecting complica-tions. Postgraduate medicine. 2004;115(4):19-27
Yıl 2018,
Cilt: 10 Sayı: 6, 34 - 36, 28.11.2018
Öz
Öz
Metabolik sendrom (MetS) diyabet ve kardiyovasküler hastalık gelişim riskini arttıran, birden fazla risk faktörünün bir arada bulunduğu bir durumdur. Dünya genelinde neredeyse her dört yetişkin bireyden birinde MetS bulunmaktadır. MetS yaygın olarak görünmesine rağmen tanı koyulmasında göz ardı edilmektedir. Bu yüzden MetS kriterlerinden herhangi birini taşıyan hastalar mutlaka metabolik sendrom penceresinden değerlendirilmelidirler. Bu çalışmada aile hekimliği polikliniğine başvuran bir hasta üzerinden birinci basamakta metabolik sendrom yönetiminin tartışılması amaçlanmıştır.
Anahtar Kelimeler
Kaynakça
- Kaynaklar 1.TEMD Obezite LM, Hipertansiyon Çalışma Grubu TÜRKİ-YE ENDOKRİNOLOJİ ve METABOLİZMA DERNEĞİ 2018. 2.Samson SL, Garber AJ. Metabolic syndrome. Endocrinologyand Metabolism Clinics. 2014;43(1):1-23. 3.Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH,Franklin BA, et al. Diagnosis and management of the meta-bolic syndrome: an American Heart Association/National He-art, Lung, and Blood Institute scientific statement. Circulati-on. 2005;112(17):2735-52. 4.Onat AT. Tıp Dünyasının Kronik Hastalıklara Yaklaşımına Ön-cülük [electronic resource]. Edited by Altan ONAT İstanbul:Logos Yayıncılık. 2017;2017:180. 5.Ford ES, Giles WH, Dietz WH. Prevalence of the metabolicsyndrome among US adults: findings from the third NationalHealth and Nutrition Examination Survey. Jama.2002;287(3):356-9. 6.Nelson MR. Managing'metabolic syndrome'and multiple riskfactors. Australian family physician. 2004;33(4):201. 7.Grundy SM. Metabolic syndrome pandemic. Arteriosclerosis,thrombosis, and vascular biology. 2008;28(4):629-36. 8.Arslan M, Atmaca A, Ayvaz G, Başkal N, Beyhan Z, Bolu E,et al. METABOLİK SENDROM KILAVUZU. 2009. 9.Reaven GM. Banting lecture 1988: role of insulin resistancein human disease. Nutrition. 1997;13(1):64. 10.Alberti KGMM, Zimmet Pf. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diag-nosis and classification of diabetes mellitus. Provisional reportof a WHO consultation. Diabetic medicine. 1998;15(7):539-53. 11.Syndrome M. Time for Action. DARWIN DEEN, MD, MS, Al-bert Einstein College of Medicine of Yeshiva University, Bronx,New York-DARWIN DEEN, MD, MS, Albert Einstein Colle-ge of Medicine of Yeshiva University, Bronx, New York. 2004. 12.Magkos F, Yannakoulia M, Chan JL, Mantzoros CS. Mana-gement of the metabolic syndrome and type 2 diabetes thro-ugh lifestyle modification. Annual review of nutrition.2009;29:223-56. 13.Bozkurt B, Aguilar D, Deswal A, Dunbar SB, Francis GS, Hor-wich T, et al. Contributory risk and management of comorbi-dities of hypertension, obesity, diabetes mellitus, hyperlipide-mia, and metabolic syndrome in chronic heart failure: a sci-entific statement from the American Heart Association. Cir-culation. 2016;134(23):e535-e78. 14.Gregg EW, Cauley JA, Stone K, Thompson TJ, Bauer DC, Cum-mings SR, et al. Relationship of changes in physical activityand mortality among older women. Jama. 2003;289(18):2379-86. 15.Willett WC, Sacks F, Trichopoulou A, Drescher G, Ferro-Luz-zi A, Helsing E, et al. Mediterranean diet pyramid: a cultu-ral model for healthy eating. The American journal of clini-cal nutrition. 1995;61(6):1402S-6S. 16.Carapetis M, Phillips P. Eat less, walk more. Enjoyable ea-ting for type 2 diabetes. Australian family physician.2002;31(12):1065. 17.Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lac-hin JM, Walker EA, et al. Reduction in the incidence of type2 diabetes with lifestyle intervention or metformin. The NewEngland journal of medicine. 2002;346(6):393-403. 18.Pearson TA, Blair SN, Daniels SR, Eckel RH, Fair JM, Fort-mann SP, et al. AHA guidelines for primary prevention of cardiovascular disease and stroke: 2002 update: consensus pa-nel guide to comprehensive risk reduction for adult patientswithout coronary or other atherosclerotic vascular diseases.Circulation. 2002;106(3):388-91. 19.Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Bee-re PA, et al. Primary prevention of acute coronary events withlovastatin in men and women with average cholesterol levels:results of AFCAPS/TexCAPS. Jama. 1998;279(20):1615-22. 20.Beckman TJ. Regular screening in type 2 diabetes: A mnemo-nic approach for improving compliance, detecting complica-tions. Postgraduate medicine. 2004;115(4):19-27
Toplam 1 adet kaynakça vardır.
Ayrıntılar
| Birincil Dil | Türkçe |
|---|---|
| Bölüm | makaleler |
| Yazarlar | |
| Yayımlanma Tarihi | 28 Kasım 2018 |
| Yayımlandığı Sayı | Yıl 2018 Cilt: 10 Sayı: 6 |
